权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Targeted Adenoviral Gene Therapy for Malignant Glioma

恶性胶质瘤的靶向腺病毒基因治疗

基本信息

批准号：
7637765
负责人：
MACIEJ S LESNIAK
金额：
$ 16.51万
依托单位：
UNIVERSITY OF CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2005
资助国家：
美国
起止时间：
2005-07-15 至 2010-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7637765
关键词：
Adenovirus Vector Adenoviruses Adult Binding Sites Biomedical Research Brain Neoplasms CAR receptor Cells Clinical Clinical Trials Data Dose Education Exhibits Fiber Funding Future Gene Delivery Generations Genes Glioblastoma Glioma Goals Grant Hospitals Immune Immune Targeting Immune response Integrins Lead Malignant Glioma Malignant Neoplasms Malignant neoplasm of brain Modality Mutation Neuraxis Neurosurgical Procedures Normal Cell Oncolytic Operative Surgical Procedures Organ Patients Peptides Predisposition Principal Investigator Publications Radiation therapy Relative (related person)Research Research Personnel Residencies Resistance Solid Specificity Testing Time Tissues Toxic effect Translating Tropism United States National Institutes of Health Viral Vector Virus base cancer therapy design gene therapy in vivo integrin beta5 neoplastic cell neurosurgery pre-clinical professor receptor research study success treatment strategy tumor vector

项目摘要

DESCRIPTION (provided by applicant): High grade gliomas represent the most common primary malignant tumor of the adult central nervous system. Unfortunately, the median survival after surgical intervention alone is only six months and the addition of radiotherapy can extend this time to only nine months. Consequently, efforts aimed at developing new therapies have focused on new treatment strategies that specifically target tumor cells and spare normal cells. One such modality, gene therapy, has shown promise in the spectrum of agents utilized against brain tumors. The success of gene therapy depends on efficient gene delivery into target cells. Viral vectors, in the form of adenoviruses, have provided one potential means for the delivery of gene therapy. Several studies, however, have demonstrated a relative resistance of brain tumors to adenoviral vectors, a finding that was subsequently attributed to the quantitative deficiency of the primary adenoviral receptor, the Coxsackie Adenovirus Receptor (CAR), on tumor cells. The main purpose of this project is to develop re-targeted adenoviral vectors with the capacity to enhance immune based cancer therapies. The focus of the re-targeting has been the expression of alpha-v-beta3 and alpha-v-beta5 on many solid organ tumors. This project aims to develop second generation adenoviruses with altered tropism for alpha-v-beta3 and alpha-v-beta5 integrins in order to achieve cell-specific targeting of immune-modulatory genes. The principal investigator, Dr. Maciej S. Lesniak, has recently completed his residency in neurological surgery and is currently as Assistant Professor of Neurosurgery at the Johns Hopkins Hospital. Dr. Lesniak immediate goals are to establish a solid research background that will allow him to become an independent investigator. By undertaking this project and furthering his scientific and biomedical research education, Dr. Lesniak hopes to one day translate this research to the clinical setting and the treatment of patients with malignant brain tumors.

描述（由申请人提供）：

项目成果

期刊论文数量（30）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Cancer stem cells: the final frontier for glioma virotherapy.

DOI：
10.1007/s12015-010-9132-7
发表时间：
2011-03
期刊：
STEM CELL REVIEWS AND REPORTS
影响因子：
4.8
作者：
Dey, Mahua;Ulasov, Ilya V.;Tyler, Matthew A.;Sonabend, Adam M.;Lesniak, Maciej S.
通讯作者：
Lesniak, Maciej S.

Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma.